Health Catalyst (HCAT) Tops Q2 EPS by 4c ; Offers Guidance

Health Catalyst (NASDAQ: HCAT) reported Q2 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $75.9 million versus the consensus estimate of $74.96 million.

GUIDANCE:

Health Catalyst sees Q3 2024 revenue of $74.5-77.5 million, versus the consensus of $77.93 million.

Health Catalyst sees FY2024 revenue of $304-312 million, versus the consensus of $307.9 million.

For earnings history and earnings-related data on Health Catalyst (HCAT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance